Search results for: Precision Medicine
Filter search results
Payment Models for Multi-Indication Therapies
1 November 2021
For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those indications. We assembled a…
OHE at iHEA: HTA in Emerging Markets, Personalised Medicine, EQ-5D mapping
6 August 2013
…Pharmaceutical Pricing in Developing Countries? from Office of Health Economics Profs Towse and Garrison both participated in a session on personalised medicine, orphan disease drugs and the future of health…
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
…were viewed to be especially valuable in the context of rising NHS spending on medicines and the challenges in agreeing a new medicine’s price, which can potentially delay patient access…
Forecasting the UK Medicines Bill to 2014
7 November 2011
…a range of projections from it. To put medicines spending in context, Jon noted that approximately 14% of NHS operating costs in Scotland for 2009/10 were for medicines, compared to…
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…(so called “Orphan Medicines”), in recognition of some of the inherent challenges around: High prices. Drug manufacturers often charge high prices for orphan medicines, in part due to the small…
A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”
1 May 2018
This OHE Consulting Report reviews “Estimated costs of production and potential prices of medicines for the World Health Organization Essential Medicines List” (Hill et al., 2018) in which the authors…
The Spanish Medicines Market Today
9 February 2011
…medicines whose retail price is less than €3.12. Expected savings from these cuts are €169m. In June 2010, new rebates were announced affecting only patented medicines reimbursed under the NHS….
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
…to innovative medicines across the European Union (EU). Since then the scope of authorisation via the centralised procedure has been broadened and made mandatory for orphan and oncology medicines. We…
Rare Disease Day 2022
28 February 2022
…Treatments for many rare conditions include the use of medicines; these medicines are referred to as orphan medicines. New innovative treatments are continually being developed, but there are a number…